INDIANAPOLIS, Aug. 30, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC) is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology (ASNC) annual meeting, September 23-26 in Philadelphia, PA.
Positron will be hosting a special ASNC 2010 symposium focused on cardiac PET, Saturday, September 25th, in the downtown Marriott Independence Ballroom at 7:00pm. Dr. Gould's lecture, "Quantitative myocardial perfusion imaging and absolute coronary flow reserve by PET, a current paradigm change in cardiovascular medicine," will be the highlight of the evening.
Dr. Gould is a renowned cardiac PET expert and a professor of cardiovascular medicine at the University of Texas Medical School in Houston. He holds the Martin Bucksbaum Distinguished University Chair (the only one in cardiology in the University of Texas system) and is executive director of the endowed Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis. His responsibilities include research, teaching, and daily hands-on performance of PET scans in his large clinical practice based on PET guided management of CAD.
Joseph Oliverio, chief technical officer of Positron states, "We are honored to have the world's foremost expert on Cardiac PET and quantitative imaging with Rb-82 speak at our symposium. Dr. Gould's talk will update the audience on the growing new paradigm for cardiac imaging as the guide to managing coronary artery disease, which is also the basis for the future release of our new comprehensive quantitative workstation."
"PET is a clear window into the heart - its past, present and future. It's a critical tool that provides the clarity and insight needed to treat and prevent coronary artery disease," stated Dr. Gould.
Routine quantitative stress PET perfusion imaging for flow in cc/min/gm and absolute coronary flow reserve (CFR) are measured routinely in every patient as the guide for revascularization procedures, second opinions, and secondary as well as primary prevention by intense, comprehensive lifestyle and pharmacologic treatment integrated with PET results and follow-up. Quantitative PET defines the level of perfusion and CFR causing ischemia and therefore the thresholds for guiding revascularization procedures or medical treatment.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.